Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials

Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis. 2016;63(11):1479-1481.

Publication Type:

Journal Article

Authors:

Grebely, Jason; Dore, Gregory J.; Zeuzem, Stefan; Aspinall, Richard J.; Fox, Raymond; Han, Lingling; McNally, John; Osinusi, Anu; Brainard, Diana M.; Subramanian, G. Mani; Natha, Macky; Foster, Graham R.; Mangia, Alessandra; Sulkowski, Mark; Feld, Jordan J.

Source:

Clin Infect Dis, Volume 63, Issue 11, p.1479-1481 (2016)

Cited On:

Key Populations: Identification and Management of HCV in People Who Inject Drugs

External Third-party Web Link:

https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciw579

Export Citation:

RIS Format

Top